BCI Regulation: Paradromics EFS vs Precision 510(k)

Updated2026-08-06

Evidence map comparing the Paradromics Connexus early feasibility study with Precision K242618 temporary cortical electrode 510k clearance — BIO original evidence map: a complete investigational BCI entering a small EFS is separated from a temporary passive cortical-electrode component receiving 510(k) clearance. Object, evidence question and claim boundary differ. Sources [1–8].

In short: Paradromics announced on June 17, 2026 that it completed the first implantation in the Connect-One EFS and reports that FDA approved the study’s IDE in November 2025. ClinicalTrials.gov describes an estimated two-person, single-group open-label study, with primary safety observation through 12 months and long-term safety follow-up through six years. Connexus remains investigational.[1][2] Precision’s Layer 7-T (K242618) received a 510(k) substantial-equivalence decision on March 30, 2025. It is a 1,024-platinum-electrode polyimide array: passive, without software or wireless capability, and intended for temporary use under 30 days.[5][6] Both are meaningful milestones, but they do not establish a regulatory ranking between the companies.

Start with the regulated object, not a headline ranking

FDA describes an early feasibility study as a small clinical investigation early in device development, generally used to obtain initial clinical safety, device-function and design information. An IDE permits an investigational device to be used in a clinical study; it is not marketing authorization.[3][4]

A 510(k) asks whether a device is substantially equivalent to a legally marketed predicate. K242618 covers the temporary cortical electrode with Device Name Layer 7-T, not the complete wireless BCI system Precision has presented.[5][6][7] A first implantation in an EFS and a component 510(k) are therefore not the same endpoint.

Paradromics: a complete investigational system enters an EFS

Paradromics announced the first implantation in the Connect-One EFS on June 17, 2026 and reports that FDA approved the study’s IDE in November 2025.[1] This wording does not claim the first-ever temporary Connexus human implantation. ClinicalTrials.gov record NCT07357428 gives an actual study start of March 31, 2026 and describes a single-group, open-label design with estimated enrollment of two participants.[2]

The registry lists device-related adverse events through 12 months as a primary safety outcome and long-term safety observation through six years. Estimated primary completion is May 2027 and estimated study completion January 2032.[2] Those are registered plans subject to change, not completed clinical results.

Precision: a temporary passive cortical array receives 510(k) clearance

FDA records show K242618 was received September 3, 2024 and reached a substantial-equivalence decision on March 30, 2025. Device Name is Layer 7-T, Classification is Electrode, Cortical, and Product Code is GYC; K191186 is identified as the predicate.[5][6]

The 510(k) summary describes 1,024 platinum electrodes on a polyimide substrate for cortical-surface recording, monitoring and stimulation, with temporary use under 30 days. It is passive, has no software or wireless communication, and is not labeled MRI compatible.[6] Precision separately says its complete wireless BCI remains investigational and is not for sale.[7]

Four claim boundaries for reporting and diligence

Name the object: complete system, implanted component, external processor or clinical procedure.[1][6][8]
Separate permission to conduct an IDE/EFS from 510(k) marketing clearance; neither should be rewritten as FDA approval of a complete system.[3][4][5]
Separate temporary under-30-day use from chronic implantation; component clearance does not replace evidence for chronic encapsulation, reliability, tissue response and system performance.[6][8]
Use company releases for announcement timing and company statements, but return to ClinicalTrials.gov and FDA decision documents for protocol design and cleared indications.[1][2][5][6]

Sources and reading boundary

Trial status, completion dates and device-development stages can change. As of August 6, 2026 this article compares public regulatory objects and evidence scope; it does not rank clinical performance, valuation or probability of commercialization.

The BIO angle

For neural-interface material teams, the transferable question goes beyond electrode count: how substrate, conductor, interconnect, encapsulation, feedthrough and tissue interface become system evidence for the intended implant duration. BIO does not claim to supply either company and does not turn a temporary-array clearance or EFS implant into regulatory endorsement of a specific material.

FAQ

Is Paradromics Connexus FDA approved for sale?

No. Paradromics reports that FDA approved the Connect-One EFS IDE in November 2025; the June 2026 milestone was the first investigational implantation in that EFS. IDE/EFS authorization permits clinical research; it is not commercial marketing approval.[1][3][4]

Does Precision’s 510(k) cover a complete wireless BCI?

No. K242618 covers the passive Layer 7-T cortical array for temporary use under 30 days, without software or wireless capability. Precision says the complete wireless system remains investigational.[6][7]

Do these milestones show which company is further ahead?

Not by themselves. One concerns early clinical feasibility of a complete investigational system; the other concerns substantial equivalence of a temporary component. The objects and evidence questions differ.[2][4][6]

BCI regulatory milestones are not a leaderboard: first Connect-One EFS implantation versus 510(k) clearance